Meeting
2019 ASCO Annual Meeting
Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.
Authors
Hamzah Abu-Sbeih
The University of Texas MD Anderson Cancer Center, Houston, TX
Hamzah Abu-Sbeih , Faisal Ali , Abdul Rafeh Naqash , Dwight Hall Owen , Sandip H. Patel , Gregory Alan Otterson , Kari Lynn Kendra , Biagio Ricciuti , Rita Chiari , Andrea De Giglio , Joseph Sleiman , Pauline Funchain , Wills Beatriz , Jiajia Zhang , Jarushka Naidoo , Jessica Philpott , Jianjun Gao , Sumit Kumar Subudhi , Yinghong Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Immunotherapy and Tumor Immunobiology
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Immune Checkpoint Inhibitors
Citation
J Clin Oncol 37, 2019 (suppl; abstr 2577)
DOI
10.1200/JCO.2019.37.15_suppl.2577
Abstract #
2577
Poster Bd #
221
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis.
First Author: Hamzah Abu-Sbeih
Poster
2021 ASCO Annual Meeting
Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.
First Author: Hamzah Abu-Sbeih
Poster
2022 ASCO Annual Meeting
Management of infliximab-refractory immune checkpoint inhibitor gastrointestinal toxicity: A multicenter case series.
First Author: Catriona Harvey
Poster
2024 ASCO Breakthrough
CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD).
First Author: Yuichiro Tsukada